# Paymentus Holdings, Inc.: financial statements, quarterly PAY · NYSE · CIK 1841156 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pay.md) · [Financials](/companies/pay/financials.md) · [Filings](/companies/pay/filings.md) · [Insiders](/companies/pay/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pay/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [152](/filings/0000950170-24-125544.md) | [165 d](/filings/0001193125-26-064510.md) | [185](/filings/0000950170-25-064979.md) | [197](/filings/0000950170-25-102218.md) | [232](/filings/0001193125-25-262925.md) | [258 d](/filings/0001193125-26-064510.md) | [275](/filings/0001193125-26-204469.md) | [280](/filings/0001193125-26-330940.md) | [311](/filings/0001193125-25-262925.md) | [330 d](/filings/0001193125-26-064510.md) | [358](/filings/0001193125-26-204469.md) | [361](/filings/0001193125-26-330940.md) | | Cost of revenue | $m | [106](/filings/0000950170-24-125544.md) | [115 d](/filings/0001193125-26-064510.md) | [132](/filings/0000950170-25-064979.md) | [139](/filings/0000950170-25-102218.md) | [171](/filings/0001193125-25-262925.md) | [192 d](/filings/0001193125-26-064510.md) | [209](/filings/0001193125-26-204469.md) | [209](/filings/0001193125-26-330940.md) | [236](/filings/0001193125-25-262925.md) | [246 d](/filings/0001193125-26-064510.md) | [272](/filings/0001193125-26-204469.md) | [266](/filings/0001193125-26-330940.md) | | Gross profit | $m | [46.9](/filings/0000950170-24-125544.md) | [49.5 d](/filings/0001193125-26-064510.md) | [52.7](/filings/0000950170-25-064979.md) | [58.8](/filings/0000950170-25-102218.md) | [60.7](/filings/0001193125-25-262925.md) | [66.0 d](/filings/0001193125-26-064510.md) | [66.0](/filings/0001193125-26-204469.md) | [71.5](/filings/0001193125-26-330940.md) | [74.8](/filings/0001193125-25-262925.md) | [84.0 d](/filings/0001193125-26-064510.md) | [86.2](/filings/0001193125-26-204469.md) | [94.3](/filings/0001193125-26-330940.md) | | Research and development | $m | [11.0](/filings/0000950170-24-125544.md) | [10.7 d](/filings/0001193125-26-064510.md) | [12.1](/filings/0000950170-25-064979.md) | [12.5](/filings/0000950170-25-102218.md) | [13.2](/filings/0001193125-25-262925.md) | [13.6 d](/filings/0001193125-26-064510.md) | [15.1](/filings/0001193125-26-204469.md) | [15.2](/filings/0001193125-26-330940.md) | [15.2](/filings/0001193125-25-262925.md) | [15.9 d](/filings/0001193125-26-064510.md) | [16.3](/filings/0001193125-26-204469.md) | [15.3](/filings/0001193125-26-330940.md) | | Operating income | $m | [5.3](/filings/0000950170-24-125544.md) | [9.1 d](/filings/0001193125-26-064510.md) | [8.3](/filings/0000950170-25-064979.md) | [10.2](/filings/0000950170-25-102218.md) | [12.1](/filings/0001193125-25-262925.md) | [14.2 d](/filings/0001193125-26-064510.md) | [15.7](/filings/0001193125-26-204469.md) | [15.9](/filings/0001193125-26-330940.md) | [19.9](/filings/0001193125-25-262925.md) | [24.1 d](/filings/0001193125-26-064510.md) | [26.6](/filings/0001193125-26-204469.md) | [32.6](/filings/0001193125-26-330940.md) | | Income tax | $m | [0.8](/filings/0000950170-24-125544.md) | [1.8 d](/filings/0001193125-26-064510.md) | [3.5](/filings/0000950170-25-064979.md) | [3.1](/filings/0000950170-25-102218.md) | [0.0](/filings/0001193125-25-262925.md) | [3.1 d](/filings/0001193125-26-064510.md) | [4.0](/filings/0001193125-26-204469.md) | [3.7](/filings/0001193125-26-330940.md) | [4.9](/filings/0001193125-25-262925.md) | [5.8 d](/filings/0001193125-26-064510.md) | [8.2](/filings/0001193125-26-204469.md) | [10.1](/filings/0001193125-26-330940.md) | | Net income | $m | [6.4](/filings/0000950170-24-125544.md) | [9.4 d](/filings/0001193125-26-064510.md) | [7.2](/filings/0001193125-25-262925.md) | [9.4](/filings/0001193125-25-262925.md) | [14.4](/filings/0001193125-25-262925.md) | [13.1 d](/filings/0001193125-26-064510.md) | [13.8](/filings/0001193125-26-330940.md) | [14.7](/filings/0001193125-26-330940.md) | [17.7](/filings/0001193125-25-262925.md) | [20.7 d](/filings/0001193125-26-064510.md) | [20.9](/filings/0001193125-26-330940.md) | [25.6](/filings/0001193125-26-330940.md) | | Diluted EPS | $ per share | [0.05](/filings/0000950170-24-125544.md) | not reported | [0.06](/filings/0000950170-25-064979.md) | [0.07](/filings/0000950170-25-102218.md) | [0.11](/filings/0001193125-25-262925.md) | not reported | [0.11](/filings/0001193125-26-204469.md) | [0.11](/filings/0001193125-26-330940.md) | [0.14](/filings/0001193125-25-262925.md) | not reported | [0.16](/filings/0001193125-26-204469.md) | [0.20](/filings/0001193125-26-330940.md) | | Basic EPS | $ per share | [0.05](/filings/0000950170-24-125544.md) | not reported | [0.06](/filings/0000950170-25-064979.md) | [0.08](/filings/0000950170-25-102218.md) | [0.12](/filings/0001193125-25-262925.md) | not reported | [0.11](/filings/0001193125-26-204469.md) | [0.12](/filings/0001193125-26-330940.md) | [0.14](/filings/0001193125-25-262925.md) | not reported | [0.17](/filings/0001193125-26-204469.md) | [0.20](/filings/0001193125-26-330940.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [162](/filings/0000950170-23-059594.md) | [179](/filings/0000950170-25-036566.md) | [180](/filings/0000950170-24-053739.md) | [189](/filings/0000950170-24-094238.md) | [188](/filings/0000950170-24-125544.md) | [206](/filings/0001193125-26-064510.md) | [246](/filings/0000950170-25-064979.md) | [266](/filings/0000950170-25-102218.md) | [288](/filings/0001193125-25-262925.md) | [321](/filings/0001193125-26-330940.md) | [339](/filings/0001193125-26-204469.md) | [378](/filings/0001193125-26-330940.md) | | Current assets | $m | [255](/filings/0000950170-23-059594.md) | [270](/filings/0000950170-25-036566.md) | [280](/filings/0000950170-24-053739.md) | [294](/filings/0000950170-24-094238.md) | [320](/filings/0000950170-24-125544.md) | [346](/filings/0001193125-26-064510.md) | [362](/filings/0000950170-25-064979.md) | [381](/filings/0000950170-25-102218.md) | [417](/filings/0001193125-25-262925.md) | [441](/filings/0001193125-26-330940.md) | [473](/filings/0001193125-26-204469.md) | [494](/filings/0001193125-26-330940.md) | | Total assets | $m | [489](/filings/0000950170-23-059594.md) | [505](/filings/0000950170-25-036566.md) | [514](/filings/0000950170-24-053739.md) | [528](/filings/0000950170-24-094238.md) | [553](/filings/0000950170-24-125544.md) | [576](/filings/0001193125-26-064510.md) | [591](/filings/0000950170-25-064979.md) | [610](/filings/0000950170-25-102218.md) | [644](/filings/0001193125-25-262925.md) | [668](/filings/0001193125-26-330940.md) | [699](/filings/0001193125-26-204469.md) | [725](/filings/0001193125-26-330940.md) | | Current liabilities | $m | [59.5](/filings/0000950170-23-059594.md) | [62.8](/filings/0000950170-25-036566.md) | [62.6](/filings/0000950170-24-053739.md) | [64.6](/filings/0000950170-24-094238.md) | [74.2](/filings/0000950170-24-125544.md) | [81.6](/filings/0001193125-26-064510.md) | [81.0](/filings/0000950170-25-064979.md) | [83.5](/filings/0000950170-25-102218.md) | [95.7](/filings/0001193125-25-262925.md) | [98.8](/filings/0001193125-26-330940.md) | [107](/filings/0001193125-26-204469.md) | [101](/filings/0001193125-26-330940.md) | | Total liabilities | $m | [71.9](/filings/0000950170-23-059594.md) | [75.2](/filings/0000950170-25-036566.md) | [74.6](/filings/0000950170-24-053739.md) | [76.1](/filings/0000950170-24-094238.md) | [84.1](/filings/0000950170-24-125544.md) | [90.7](/filings/0001193125-26-064510.md) | [90.5](/filings/0000950170-25-064979.md) | [92.8](/filings/0000950170-25-102218.md) | [107](/filings/0001193125-25-262925.md) | [107](/filings/0001193125-26-330940.md) | [115](/filings/0001193125-26-204469.md) | [112](/filings/0001193125-26-330940.md) | | Shareholders' equity | $m | [417](/filings/0000950170-24-125544.md) | [430](/filings/0001193125-26-064510.md) | [439](/filings/0001193125-25-262925.md) | [452](/filings/0001193125-25-262925.md) | [469](/filings/0001193125-25-262925.md) | [486](/filings/0001193125-26-330940.md) | [500](/filings/0001193125-26-330940.md) | [517](/filings/0001193125-26-330940.md) | [537](/filings/0001193125-25-262925.md) | [560](/filings/0001193125-26-330940.md) | [583](/filings/0001193125-26-330940.md) | [613](/filings/0001193125-26-330940.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [13.1 d](/filings/0000950170-24-125544.md) | [24.4 d](/filings/0001193125-26-064510.md) | [11.0](/filings/0000950170-25-064979.md) | [18.0 d](/filings/0000950170-25-102218.md) | [6.7 d](/filings/0001193125-25-262925.md) | [27.9 d](/filings/0001193125-26-064510.md) | [50.4](/filings/0001193125-26-204469.md) | [31.5 d](/filings/0001193125-26-330940.md) | [35.1 d](/filings/0001193125-25-262925.md) | [45.1 d](/filings/0001193125-26-064510.md) | [30.5](/filings/0001193125-26-204469.md) | [48.9 d](/filings/0001193125-26-330940.md) | | Capital expenditure | $m | [0.2 d](/filings/0000950170-24-125544.md) | [0.1 d](/filings/0001193125-26-064510.md) | [0.1](/filings/0000950170-25-064979.md) | [0.2 d](/filings/0000950170-25-102218.md) | [0.1 d](/filings/0001193125-25-262925.md) | [0.1 d](/filings/0001193125-26-064510.md) | [0.1](/filings/0001193125-26-204469.md) | [0.1 d](/filings/0001193125-26-330940.md) | [0.1 d](/filings/0001193125-25-262925.md) | [0.1 d](/filings/0001193125-26-064510.md) | [0.1](/filings/0001193125-26-204469.md) | [0.1 d](/filings/0001193125-26-330940.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [123](/filings/0000950170-23-059594.md) | [124](/filings/0000950170-24-053739.md) | [124](/filings/0000950170-24-094238.md) | [126](/filings/0000950170-24-125544.md) | [127](/filings/0000950170-25-064979.md) | [127](/filings/0000950170-25-102218.md) | [128](/filings/0001193125-25-262925.md) | [129](/filings/0001193125-26-204469.md) | [129](/filings/0001193125-26-330940.md) | [129](/filings/0001193125-25-262925.md) | [129](/filings/0001193125-26-204469.md) | [129](/filings/0001193125-26-330940.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.